Hypoxia-driven gene expression is an independent prognostic factor in stage II and III colon cancer patients

Clinical Cancer Research

Volumn 20, Issue 8, 2014, Pages 2159-2168

  Dekervel, Jeroen ^a   Hompes, Daphne ^c   Van Malenstein, Hannah ^a   Popovic, Dusan ^b   Sagaert, Xavier ^d   De Moor, Bart ^b   Van Cutsem, Eric ^a   D'Hoore, Andre ^c   Verslype, Chris ^a   Van Pelt, Jos ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Departments of Abdominal Surgical Oncology   (United States)

^d Departments of Imaging and Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE METHYLTRANSFERASE; PROTEIN P53; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; ARTICLE; BCCIP GENE; BIOINFORMATICS; BNIP3L GENE; BTBD14A GENE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL STRAIN CACO 2; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; DDIT4 GENE; DISEASE FREE SURVIVAL; ERRFI1 GENE; FAM46C GENE; FEMALE; GADD45B GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; HBP1 GENE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HYPOXIA; ING5 GENE; INSIG2 GENE; KLF7 GENE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MPHOSPH6 GENE; NNMT GENE; P4HA1 GENE; P4HA2 GENE; PLAUR GENE; PRIORITY JOURNAL; RHOU GENE; TMCC1 GENE; TP53 GENE; UBE2H GENE; ULBP2 GENE; VALIDATION PROCESS; XIAP GENE; ANOXIA; CACO 2 CELL LINE; CELL HYPOXIA; COLONIC NEOPLASMS; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL MODEL; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANOXIA; CACO-2 CELLS; CELL HYPOXIA; COHORT STUDIES; COLONIC NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84898948509     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2958     Document Type: Article

References (26)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN2008. Int J Cancer 2010;127:2893-917.
2. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012;23:2479-516.
3. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
4. Quasar Collaborative G, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370:2020-9.
5. Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 2010;15:390-404.
6. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
7. Sanz-Pamplona R, Berenguer A, Cordero D, Riccadonna S, Sole X, Crous-Bou M, et al. Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. PLoS ONE 2012; 7:e48877.
8. Black ER, Falzon L, Aronson N. Gene Expression Profiling for Predicting Outcomes in Stage II Colon Cancer. Rockville MD; 2012.
9. van Malenstein H, Gevaert O, Libbrecht L, Daemen A, Allemeersch J, Nevens F, et al. A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinoma. Clin Cancer Res 2010;16:4278-88.
10. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012;33: 207-14.
11. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995;57:289-300.
12. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005;93:387-91.
13. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, et al. Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer. Clin Cancer Res 2009;15:7642-51.
14. Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 2007;8:R131.
15. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010;138:958-68.
16. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 2004;20:93-9.
17. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with colorcoded probe pairs. Nat Biotechnol 2008;26:317-25.
18. De Sousa EMF, WangX, Jansen M, Fessler E, Trinh A, de Rooij LP, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013;19:614-8.
19. Liu Y, Bodmer WF. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci U S A 2006;103:976-81.
20. Sarasqueta AF, Forte G, Corver WE, de Miranda NF, Ruano D, van Eijk R, et al. Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer. BMC Cancer 2013;13:277.
21. Moon EJ, Brizel DM, Chi JT, DewhirstMW.The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal 2007;9:1237-94.
22. Yoshimura H, Dhar DK, Kohno H, Kubota H, Fujii T, Ueda S, et al. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 2004;10: 8554-60.
23. Sermeus A, Michiels C. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2011;2:e164.
24. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013;19:619-25.
25. Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 2013;10:e1001453.
26. Budinska E, Popovici V, Tejpar S, D'Ario G, Lapique N, Sikora KO, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 2013;231:63-76.